Coversin Dual-Specific Antibody for Autoimmune Blistering Disease Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for autoimmune blistering diseases (AIBD) are inadequate, as they lack specificity and often come with significant side effects, and there is a need for therapies that target the complement pathway and leukotriene B4 (LTB4) to effectively manage and prevent these diseases.
Innovation Solution
The use of Coversin, a protein derived from ticks that inhibits both the complement pathway by binding to C5 and LTB4, offering a dual inhibitory action to reduce the affected body surface area in AIBD, either alone or in combination with other treatments.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for AIBD are used, then disease symptoms are addressed, but specificity is lacking and significant side effects occur
Solution Approach 1:
The invention segments the treatment approach by targeting two distinct pathological pathways (complement pathway via C5 and LTB4 pathway) separately through a dual-specificity antibody, rather than using non-specific immunosuppressants. This segmented targeting improves reliability while reducing harmful side effects by precisely addressing disease mechanisms.
Solution Approach 2:
The dual-specificity antibody exhibits local quality by having different binding specificities (C5 and LTB4) within a single molecular structure. This allows the treatment to act differently on two distinct pathological pathways, providing targeted therapy that improves effectiveness while minimizing broad immunosuppression and associated side effects.
2Reliability
If therapies targeting complement pathway and LTB4 are implemented, then disease management is improved, but treatment complexity increases
Solution Approach 1:
The invention merges two separate therapeutic targets (C5 and LTB4) into a single dual-specificity antibody molecule. This combining approach improves disease management by simultaneously addressing both complement and leukotriene pathways, while actually simplifying treatment complexity by using one agent instead of multiple separate therapies.
Solution Approach 2:
The dual-specificity antibody exhibits multi-functionality by binding to both C5 and LTB4, making it a universal treatment that addresses multiple pathological mechanisms of AIBD. This universality improves disease management comprehensively while maintaining treatment simplicity through a single multi-functional agent.
3Reliability
If dual inhibitory action on C5 and LTB4 is used, then affected body surface area is reduced more effectively, but manufacturing complexity increases
Solution Approach 1:
The dual-specificity antibody combines two inhibitory functions (anti-C5 and anti-LTB4) into a single molecular entity that can be manufactured through unified recombinant DNA technology. This merging improves effectiveness by providing dual action, while the standardized biomanufacturing process for recombinant proteins maintains ease of manufacture despite the enhanced functionality.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Coversin demonstrates greater effectiveness in reducing the affected body surface area in AIBD compared to existing treatments, such as Zileuton and methylprednisolone, and can be administered prophylactically or therapeutically to manage the disease, potentially reducing the need for other treatments and their associated side effects.
Implementation Method 1
The complement system is activated by the presence of foreign antigens. Three activation pathways exist: (1) the classical pathway which is activated by IgM and IgG complexes or by recognition of carbohydrates; (2) the alternative pathway which is activated by non-self surfaces (lacking specific regulatory molecules) and by bacterial endotoxins; and (3) the lectin pathway which is activated by binding of mannan-binding lectin (MBL) to mannose residues on the surface of a pathogen.
Implementation Method 2
Leukotriene B4 (LTB4) is the most powerful chemotactic and chemokinetic eicosanoid described and promotes adhesion of neutrophils to the vascular endothelium via upregulation of integrins. It is also a complete secretagogue for neutrophils, induces their aggregation and increases microvascular permeability.
Data Source
Figure 1
Figure 2A
Figure 2B
AI summary
The present invention relates to methods of treating or preventing AIBD.